SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

 Division of Infectious Diseases

[Return To Index page]
photo John W. Mellors, MD

Professor of Medicine

Chief, Division Infectious Diseases

Endowed Chair for Global Elimination of HIV and AIDS

Email: mellors@dom.pitt.edu

Phone: 412-624-8512

Contact
Office: Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-624-8512
Fax: 412-383-7982
E-mail: mellors@dom.pitt.edu
Administrative Assistant:
Heather C. Meyers
Address: S818, Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Email: hem63@pitt.edu
Phone: 412-383-7963
Fax: 412-383-7962
Administrative Assistant:
Lorraine M Pollini
Address: S817-B, Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Phone: 412-624-2029
Fax: 412-383-7962
Education and Training
Education
BA, Dartmouth College, Hanover, NH, 1975
MD, Dartmouth Medical School, Hanover, NH, 1978
Training
Internship/Residency Training, Yale-New Haven Hospital, New Haven, CT, 1982
Infectious Diseases Fellowship Training, Yale University School of Medicine, New Haven, CT, 1985
Research Interest
Dr. Mellors led several studies with samples from the multicenter AIDS cohort study (MACS) that established the critical relationship between plasma viremia (HIV-1 RNA) and HIV disease progression to AIDS and death in both acute and chronic HIV-1 infection. This work led to the universal use of plasma HIV-1 RNA and CD4+T-cell counts to estimate prognosis in HIV-1 infection and the optimal time to initiate antiretroviral therapy (ART). Dr. Mellors contributed to the development and testing of the first antiretroviral combinations that produced sustained suppression of viremia and recovery of CD4+T-cells that launched the current era of highly-effective ART.

Presently, Dr. Mellors’ laboratory focuses on resistance to antiretroviral drugs used for treatment and HIV prevention and on mechanisms of HIV persistence and strategies to deplete the reservoirs that are the barrier to curing HIV infection. His work on HIV reservoirs showed that low-level viremia persists in most individuals on long-term suppressive ART and that the level of residual viremia is predicted by the level of viremia before ART. Current work focuses on identifying agents to reverse HIV latency and to eliminate HIV infected cells. The impact of innovative therapies on HIV reservoirs is being studied in Phase I/II trials of histone deacetylase inhibitors, monoclonal antibodies to immune checkpoint ligands, monoclonal antibodies to HIV envelope glycoproteins, and TLR agonists.
Clinical Interest
Dr. Mellors is the Chief of the Infectious Diseases Division and Executive Director of the HIV/AIDS Program with the University of Pittsburgh Medical Center (UPMC), positions he has held since 1999. Under his leadership, the Division has grown to over 30 faculty, with $3 million in annual clinical revenue.
Dr. Mellors directs the primary care and clinical research activities in HIV/AIDS at UPMC Health System, providing care to over 1400 HIV-infected individuals. His clinical interests are directed towards optimizing antiretroviral therapy of HIV infection, especially among individual with antiretoviral drug resistance
Educational Interest
Dr. Mellors is a tenured Professor of Medicine, Pathology, and Infectious Diseases and Microbiology, who has as a strong reputation as a knowledgeable and enthusiastic mentor and teacher at the University of Pittsburgh. He has lectured on “HIV-AIDS” in the Medical Microbiology course, “HIV-1 Antiviral Strategies” in the Retrovirology course of the Molecular Virology and Microbiology program and “HIV Cure” in the Prevention, Treatment, and Control of Global Infectious Diseases course within the Department of Infectious Diseases and Microbiology curriculum. Dr. Mellors has a long history of mentorship of fellows, residents and medical students. He has mentored six post-doctoral fellows, eleven pre-doctoral candidates, and serves on numerous dissertation committees.

Dr. Mellors offers trainees balanced guidance in the areas of research, authorship, grant writing, manuscript review and oral presentation based upon his extensive professional experience. Currently, one PhD student, a recipient of the Pitt AIDS Research Training (PART) Program award for pre-doctoral trainees, one Medical student, a recipient of two years of funding via the Medical Research Fellows Program awarded by the Howard Hughes Medical Institute (HHMI), and one post-doctoral associate, are benefiting from Dr. Mellors primary mentorship.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Mellors JW. Randomized trial of treatment interruption prior to optimized antiretroviral therapy for persons with drug-resistant HIV: 48 week virologic results of ACTG A5086. J Inf Dis 2006; 194:1309-18. J Inf Dis. 2006; 194: 1309-18.
McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS. 2006; 20: 2331-5.
Sluis-Cremer N, Sheen CW, Zelina S, Torres PSAQ, Parikh UM, Mellors JW. Molecular mechanism by which K70E in HIV-1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007; 51 PMCID: PMC1797654: 48-53.
Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Mellors JW. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007; 3(4) PMCID: PMC1847689: 46.
Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular Mechanisms of Bi-Directional Antagonism between K65R and Thymidine Analog Mutations in HIV-1 Reverse Transcriptase. AIDS. 2007; 21 PMID 17589186: 1405-1414.
Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Munoz A. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell slope for progression to AIDS and death in untreated HIV-1 infection. JAMA. 2007; 297 (21): 2349-50.
Margolis DM, Mukherjee L, Fltecher CV, Hogg E, Ogata-Arakaki D, Petersen T, Russin D, Martinez A, Mellors JW for the ACTG 5165 Team. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenylate mofetil in drug-resistant HIV infection. AIDS. 2007; 21 PMID: 17885292: 2025-2032.
Brehm J, Koontz D, Meteer JD, Pithak V, Sluis-Cremer N, Mellors JW. Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase that Increase Resistance to 3'-Azido-3'-Dideoxythymidine. J Virol. 2007; 81 PMCID PMC1951314: 7852-9.
Abbas UL, Anderson RM, Mellors JW. Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS ONE. 2007; 2(9) PMCID: PMC1975470: 875.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Mellors JW for the ACTG A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. New Eng J Med. 2008; 358: 2095-2106.
Sponsored Research/Activities
Title: Comprehensive Assessment of Resistance Risk and Development of Policy Recommendations for Microbicide/PrEP Roll Out
Role: Principal Investigator
Funding Agency: United States Agency International Development
Start Year: 2015
End Year: 2020
Title: Latent Reservoir Characterization and Correlations with Neuropsychiatric Function and Thymic Output over 12 Years in HIV-Infected Children Given Early Antiretroviral Treatment in South Africa
Role: Principal Investigator
Funding Agency: Stellenbosch University/National Institute of Mental Health
Grant Number: R01 MH105134
Start Year: 2014
End Year: 2017
Title: Simplified Assays of Latent But Inducible HIV-1 Reservoirs
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI113102
Start Year: 2014
End Year: 2016
Title: ACTG Protocol A5326 - Safety and Immunotherapeutic Activity of an Anti-PD-L1 Antibody in HIV-1 Infected Subjects on Suppressive cART
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2016
Title: AIDS Clinical Trial Group: ACTG 5315-5321 Protocol Chair Salary Support
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2015
Title: AIDS Clinical Trials Group: ACTG - TSG Cure
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2014
Title: Bench to Bedside: Localizing Reservoirs of HIV Persistence in Lymphoid Tissue (Supplement)
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI069494
Start Year: 2013
End Year: 2020
Title: Hormonal Contraception, Pre-Exposure Prophylaxis, and HIV-1 Protection
Role: Principal Investigator
Funding Agency: University of Washington/National Institute of Child Health & Human Development
Grant Number: R21 HD074439
Start Year: 2013
End Year: 2015
Title: Decay of HIV-1 Reservoirs in Subjects on Long-Term Antiretroviral Therapy: AHRC Study: A5321 Protocol Vice-Chair Support
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2013
End Year: 2013
Title: Mechanisms of HIV Drug Resistance
Role: Principal Investigator
Funding Agency: Leidos Biomedical Research, Inc./National Cancer Institute
Start Year: 2012
End Year: 2016
Title: HIV Reservoirs and Viral Eradication Transformative Science Group
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2011
End Year: 2013
Title: University of Pittsburgh Clinical Trials Unit
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI069494
Start Year: 2009
End Year: 2013
Title: Rational Design of NRTI for Drug Resistant HIV-1
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI071846
Start Year: 2007
End Year: 2013
Title: University of Pittsburgh Clinical Trials Unit
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI069494
Start Year: 2007
End Year: 2013
Title: ACTG Task Order 5207
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI068636
Start Year: 2007
End Year: 2012
Title: University of Pittsburgh Virology Specialty Laboratory
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2006
End Year: 2013
Title: NCI HIV Drug Resistance Program
Role: Principal Investigator
Funding Agency: SAIC Frederick Cancer R&D Center
Grant Number: N01 N01-CO-12400
Start Year: 2005
End Year: 2012
Title: Longitudinal Evaluation of HIV-Associated Lung Disease Phenotypes
Role: Co-Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL125049
Start Year: 2014
End Year: 2018
Title: Novel Mechanisms of HIV Resistance to RTIs
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI081571
Start Year: 2015
End Year: 2019
Title: MTN Virology Core
Role: Co-Investigator
Funding Agency: Magee Womens Hospital/National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI106707
Start Year: 2014
End Year: 2020
Title: University of Pittsburgh Multicenter AIDS Cohort Study (MACS)
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI035041
Start Year: 2014
End Year: 2019
Title: Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI1110410
Start Year: 2014
End Year: 2018
Title: Multicenter AIDS Cohort Study
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI035041
Start Year: 2009
End Year: 2014
Title: Microbicide Trials Network Virology Core
Role: Co-Investigator
Funding Agency: Magee Womens Hospital/National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI068633
Start Year: 2006
End Year: 2016
Notable Achievements
Chair, AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG), 2011-2014
Recipient of National Institutes of Health National Cancer Institute Award of Merit, 2015
Endowed Chair for Global Elimination of HIV and AIDS, 2016